Abstract
Inflammatory bowel disease is a group of long-term systemic inflammatory disorders affecting the gastrointestinal tract, including Crohn's disease and ulcerative colitis, which may be associated with an increased risk of developing extraintestinal manifestations, including cardiovascular disease, thereby decreasing the quality of life. Pathophysiological changes associated with inflammatory bowel disease include alterations of the microbiome, endotoxemia, and changes to glucose and lipid metabolism. Inflammatory bowel disease patients have higher carotid intima-media thickness, lower flow-mediated dilatation, and increased carotid-femoral pulse wave velocity, which are markers of elevated cardiovascular risk. In addition, inflammatory bowel disease patients are at an increased risk for developing venous and arterial thrombotic events due to a hypercoagulable state caused by thrombocytosis and coagulation system activation. To reduce the risk of developing cardiovascular disease, lifestyle modifications, such as smoking cessation, dietary changes, and increased physical activity alongside management with appropriate medication, should be considered. This paper examines how inflammatory bowel disease can influence the risk of cardiovascular complications and the involvement of drug therapy.
Methods: PubMed was searched using keywords, such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, cardiovascular disease, pericarditis, thromboembolism, and many more. Relevant literature up to March 2023 has been examined and summarized, which consisted of data from various clinical trials, meta-analyses, retrospective/prospective cohort studies, and current guidelines.
Graphical Abstract
[1]
Fabián O, Kamaradová K. Morphology of inflammatory bowel diseases (IBD). Cesk Patol 2022; 58(1): 27-37.
[PMID: 35387455]
[PMID: 35387455]
[2]
Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care 2017; 44(4): 673-92.
[http://dx.doi.org/10.1016/j.pop.2017.07.010] [PMID: 29132528]
[http://dx.doi.org/10.1016/j.pop.2017.07.010] [PMID: 29132528]
[3]
Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5(1): 17-30.
[http://dx.doi.org/10.1016/S2468-1253(19)30333-4] [PMID: 31648971]
[http://dx.doi.org/10.1016/S2468-1253(19)30333-4] [PMID: 31648971]
[4]
Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126(6): 1504-17.
[http://dx.doi.org/10.1053/j.gastro.2004.01.063] [PMID: 15168363]
[http://dx.doi.org/10.1053/j.gastro.2004.01.063] [PMID: 15168363]
[5]
Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn’s disease. Am Fam Physician 2011; 84(12): 1365-75.
[PMID: 22230271]
[PMID: 22230271]
[6]
Veauthier B, Hornecker JR. Crohn’s disease: Diagnosis and management. Am Fam Physician 2018; 98(11): 661-9.
[PMID: 30485038]
[PMID: 30485038]
[7]
Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol 2020; 35(3): 380-9.
[http://dx.doi.org/10.1111/jgh.14872] [PMID: 31596960]
[http://dx.doi.org/10.1111/jgh.14872] [PMID: 31596960]
[8]
Barnes EL, Loftus EV Jr, Kappelman MD. Effects of race and ethnicity on diagnosis and management of inflammatory bowel diseases. Gastroenterology 2021; 160(3): 677-89.
[PMID: 33098884]
[PMID: 33098884]
[9]
Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 years - United States, 2015. MMWR Morb Mortal Wkly Rep 2016; 65(42): 1166-9.
[http://dx.doi.org/10.15585/mmwr.mm6542a3] [PMID: 27787492]
[http://dx.doi.org/10.15585/mmwr.mm6542a3] [PMID: 27787492]
[10]
Ghouri YA, Tahan V, Shen B. Secondary causes of inflammatory bowel diseases. World J Gastroenterol 2020; 26(28): 3998-4017.
[http://dx.doi.org/10.3748/wjg.v26.i28.3998] [PMID: 32821067]
[http://dx.doi.org/10.3748/wjg.v26.i28.3998] [PMID: 32821067]
[11]
Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013; 10(10): 585-95.
[http://dx.doi.org/10.1038/nrgastro.2013.117] [PMID: 23835489]
[http://dx.doi.org/10.1038/nrgastro.2013.117] [PMID: 23835489]
[12]
Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15(1): 63-8.
[http://dx.doi.org/10.1002/ibd.20604] [PMID: 18626963]
[http://dx.doi.org/10.1002/ibd.20604] [PMID: 18626963]
[13]
Singh S, Singh H, Loftus EV Jr, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12(3): 382-393.e1.
[http://dx.doi.org/10.1016/j.cgh.2013.08.023] [PMID: 23978350]
[http://dx.doi.org/10.1016/j.cgh.2013.08.023] [PMID: 23978350]
[14]
Czubkowski P, Osiecki M. Szymańska E, Kierkuś J. The risk of cardiovascular complications in inflammatory bowel disease. Clin Exp Med 2020; 20(4): 481-91.
[http://dx.doi.org/10.1007/s10238-020-00639-y] [PMID: 32785793]
[http://dx.doi.org/10.1007/s10238-020-00639-y] [PMID: 32785793]
[15]
Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: Mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015; 36(8): 482-9.
[http://dx.doi.org/10.1093/eurheartj/ehu403] [PMID: 25433021]
[http://dx.doi.org/10.1093/eurheartj/ehu403] [PMID: 25433021]
[16]
Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res 2015; 46(5): 328-38.
[http://dx.doi.org/10.1016/j.arcmed.2015.06.006] [PMID: 26135634]
[http://dx.doi.org/10.1016/j.arcmed.2015.06.006] [PMID: 26135634]
[17]
Wagenaar CA, van de Put M, Bisschops M, et al. The effect of dietary interventions on chronic inflammatory diseases in relation to the microbiome: A systematic review. Nutrients 2021; 13(9): 3208.
[http://dx.doi.org/10.3390/nu13093208] [PMID: 34579085]
[http://dx.doi.org/10.3390/nu13093208] [PMID: 34579085]
[18]
Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol 2020; 145(1): 16-27.
[http://dx.doi.org/10.1016/j.jaci.2019.11.003] [PMID: 31910984]
[http://dx.doi.org/10.1016/j.jaci.2019.11.003] [PMID: 31910984]
[19]
Peng L, Li ZR, Green RS, Holzmanr IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009; 139(9): 1619-25.
[http://dx.doi.org/10.3945/jn.109.104638] [PMID: 19625695]
[http://dx.doi.org/10.3945/jn.109.104638] [PMID: 19625695]
[20]
Cainzos-Achirica M, Glassner K, Zawahir HS, et al. Inflammatory bowel disease and atherosclerotic cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol 2020; 76(24): 2895-905.
[http://dx.doi.org/10.1016/j.jacc.2020.10.027] [PMID: 33303079]
[http://dx.doi.org/10.1016/j.jacc.2020.10.027] [PMID: 33303079]
[21]
Łykowska-Szuber L, Rychter AM, Dudek M, et al. What links an increased cardiovascular risk and inflammatory bowel disease? A narrative review. Nutrients 2021; 13(8): 2661.
[http://dx.doi.org/10.3390/nu13082661] [PMID: 34444821]
[http://dx.doi.org/10.3390/nu13082661] [PMID: 34444821]
[22]
Pussinen PJ, Kopra E, Pietiäinen M, et al. Periodontitis and cardiometabolic disorders: The role of lipopolysaccharide and endotoxemia. Periodontol 2000 2022; 89(1): 19-40.
[http://dx.doi.org/10.1111/prd.12433] [PMID: 35244966]
[http://dx.doi.org/10.1111/prd.12433] [PMID: 35244966]
[23]
Long SL, Gahan CGM, Joyce SA. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med 2017; 56: 54-65.
[http://dx.doi.org/10.1016/j.mam.2017.06.002] [PMID: 28602676]
[http://dx.doi.org/10.1016/j.mam.2017.06.002] [PMID: 28602676]
[24]
Chiang JYL. Bile acid metabolism and signaling. Compr Physiol 2013; 3(3): 1191-212.
[http://dx.doi.org/10.1002/cphy.c120023] [PMID: 23897684]
[http://dx.doi.org/10.1002/cphy.c120023] [PMID: 23897684]
[25]
Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34(33): 2636-48.
[http://dx.doi.org/10.1093/eurheartj/eht210]
[http://dx.doi.org/10.1093/eurheartj/eht210]
[26]
Bracamonte-Baran W, Čiháková D. Cardiac autoimmunity: Myocarditis. Adv Exp Med Biol 2017; 1003: 187-221.
[http://dx.doi.org/10.1007/978-3-319-57613-8_10] [PMID: 28667560]
[http://dx.doi.org/10.1007/978-3-319-57613-8_10] [PMID: 28667560]
[27]
Wu GC, Leng RX, Lu Q, Fan YG, Wang DG, Ye DQ. Subclinical atherosclerosis in patients with inflammatory bowel diseases: A systematic review and meta-analysis. Angiology 2017; 68(5): 447-61.
[http://dx.doi.org/10.1177/0003319716652031] [PMID: 27252243]
[http://dx.doi.org/10.1177/0003319716652031] [PMID: 27252243]
[28]
Nezu T, Hosomi N, Aoki S, Matsumoto M. Carotid intima-media thickness for atherosclerosis. J Atheroscler Thromb 2016; 23(1): 18-31.
[http://dx.doi.org/10.5551/jat.31989] [PMID: 26460381]
[http://dx.doi.org/10.5551/jat.31989] [PMID: 26460381]
[29]
Korkmaz H, Onalan O. Evaluation of endothelial dysfunction: Flow-mediated dilation. Endothelium 2008; 15(4): 157-63.
[http://dx.doi.org/10.1080/10623320802228872] [PMID: 18663619]
[http://dx.doi.org/10.1080/10623320802228872] [PMID: 18663619]
[30]
Millasseau SC, Stewart AD, Patel SJ, Redwood SR, Chowienczyk PJ. Evaluation of carotid-femoral pulse wave velocity: Influence of timing algorithm and heart rate. Hypertension 2005; 45(2): 222-6.
[http://dx.doi.org/10.1161/01.HYP.0000154229.97341.d2] [PMID: 15642772]
[http://dx.doi.org/10.1161/01.HYP.0000154229.97341.d2] [PMID: 15642772]
[31]
Ozturk K, Guler AK, Cakir M, et al. Pulse wave velocity, intima media thickness, and flow-mediated dilatation in patients with normotensive normoglycemic inflammatory bowel disease. Inflamm Bowel Dis 2015; 21(6): 1.
[http://dx.doi.org/10.1097/MIB.0000000000000355] [PMID: 25803507]
[http://dx.doi.org/10.1097/MIB.0000000000000355] [PMID: 25803507]
[32]
Senchenkova E, Seifert H, Granger D. Hypercoagulability and platelet abnormalities in inflammatory bowel disease. Semin Thromb Hemost 2015; 41(6): 582-9.
[http://dx.doi.org/10.1055/s-0035-1556590] [PMID: 26270113]
[http://dx.doi.org/10.1055/s-0035-1556590] [PMID: 26270113]
[33]
Voudoukis E, Karmiris K, Koutroubakis IE. Multipotent role of platelets in inflammatory bowel diseases: A clinical approach. World J Gastroenterol 2014; 20(12): 3180-90.
[http://dx.doi.org/10.3748/wjg.v20.i12.3180] [PMID: 24696603]
[http://dx.doi.org/10.3748/wjg.v20.i12.3180] [PMID: 24696603]
[34]
Thapa SD, Hadid H, Imam W, et al. Persistent reactive thrombocytosis may increase the risk of coronary artery disease among inflammatory bowel disease patients. Dig Dis Sci 2015; 60(10): 3062-8.
[http://dx.doi.org/10.1007/s10620-015-3701-1] [PMID: 25972153]
[http://dx.doi.org/10.1007/s10620-015-3701-1] [PMID: 25972153]
[35]
Singh S, Blanchard A, Walker JR, Graff LA, Miller N, Bernstein CN. Common symptoms and stressors among individuals with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2011; 9(9): 769-75.
[http://dx.doi.org/10.1016/j.cgh.2011.05.016] [PMID: 21645640]
[http://dx.doi.org/10.1016/j.cgh.2011.05.016] [PMID: 21645640]
[36]
Vavricka SR, Galván JA, Dawson H, et al. Expression patterns of TNFα MAdCAM1, and STAT3 in intestinal and skin manifestations of inflammatory bowel disease. J Crohn’s Colitis 2018; 12(3): 347-54.
[http://dx.doi.org/10.1093/ecco-jcc/jjx158] [PMID: 29182760]
[http://dx.doi.org/10.1093/ecco-jcc/jjx158] [PMID: 29182760]
[37]
Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol 2011; 7(4): 235-41.
[PMID: 21857821]
[PMID: 21857821]
[38]
Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: A population-based nationwide study. Gut 2011; 60(7): 937-43.
[http://dx.doi.org/10.1136/gut.2010.228585] [PMID: 21339206]
[http://dx.doi.org/10.1136/gut.2010.228585] [PMID: 21339206]
[39]
Chen B, Collen LV, Mowat C, et al. Inflammatory bowel disease and cardiovascular diseases. Am J Med 2022; 135(12): 1453-60.
[http://dx.doi.org/10.1016/j.amjmed.2022.08.012] [PMID: 36058305]
[http://dx.doi.org/10.1016/j.amjmed.2022.08.012] [PMID: 36058305]
[40]
Vizzardi E, Sciatti E, Bonadei I, et al. Subclinical cardiac involvement in Crohn’s disease and ulcerative colitis: An echocardiographic case-control study. Panminerva Med 2016; 58(2): 115-20.
[PMID: 26964076]
[PMID: 26964076]
[41]
Lee MT, Mahtta D, Chen L, et al. Premature atherosclerotic cardiovascular disease risk among patients with inflammatory bowel disease. Am J Med 2021; 134(8): 1047-1051.e2.
[http://dx.doi.org/10.1016/j.amjmed.2021.02.029] [PMID: 33812865]
[http://dx.doi.org/10.1016/j.amjmed.2021.02.029] [PMID: 33812865]
[42]
Aniwan S, Pardi DS, Tremaine WJ, Loftus EV Jr. Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018; 16(10): 1607-1615.e1.
[http://dx.doi.org/10.1016/j.cgh.2018.04.031] [PMID: 29702298]
[http://dx.doi.org/10.1016/j.cgh.2018.04.031] [PMID: 29702298]
[43]
Feng W, Chen G, Cai D, Zhao S, Cheng J, Shen H. Inflammatory bowel disease and risk of ischemic heart disease: An updated meta-analysis of cohort studies. J Am Heart Assoc 2017; 6(8): e005892.
[http://dx.doi.org/10.1161/JAHA.117.005892] [PMID: 28768646]
[http://dx.doi.org/10.1161/JAHA.117.005892] [PMID: 28768646]
[44]
Kristensen SL, Lindhardsen J, Ahlehoff O, et al. Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: A nationwide study. Europace 2014; 16(4): 477-84.
[http://dx.doi.org/10.1093/europace/eut312] [PMID: 24108228]
[http://dx.doi.org/10.1093/europace/eut312] [PMID: 24108228]
[45]
Ekmen N, Can G, Can H, et al. Is there any link between atrial arrhythmias and inflammatory bowel disease? Saudi J Gastroenterol 2021; 27(5): 289-95.
[http://dx.doi.org/10.4103/sjg.sjg_622_20] [PMID: 34596593]
[http://dx.doi.org/10.4103/sjg.sjg_622_20] [PMID: 34596593]
[46]
Pemmasani G, Elgendy I, Mamas MA, Leighton JA, Aronow WS, Tremaine WJ. Epidemiology and clinical outcomes of patients with inflammatory bowel disease presenting with acute coronary syndrome. Inflamm Bowel Dis 2021; 27(7): 1017-25.
[http://dx.doi.org/10.1093/ibd/izaa237] [PMID: 32978941]
[http://dx.doi.org/10.1093/ibd/izaa237] [PMID: 32978941]
[47]
Kumar A, Lukin DJ. Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2020; 32(2): 205-15.
[http://dx.doi.org/10.1097/MEG.0000000000001648] [PMID: 31851091]
[http://dx.doi.org/10.1097/MEG.0000000000001648] [PMID: 31851091]
[48]
Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: A Danish Nationwide Cohort study. Circ Heart Fail 2014; 7(5): 717-22.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.114.001152] [PMID: 25052190]
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.114.001152] [PMID: 25052190]
[49]
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142(1): 46-54.e42.
[http://dx.doi.org/10.1053/j.gastro.2011.10.001] [PMID: 22001864]
[http://dx.doi.org/10.1053/j.gastro.2011.10.001] [PMID: 22001864]
[50]
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis 2017; 11(6): 649-70.
[http://dx.doi.org/10.1093/ecco-jcc/jjx008] [PMID: 28158501]
[http://dx.doi.org/10.1093/ecco-jcc/jjx008] [PMID: 28158501]
[51]
Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 2010; 35(2): 72-115.
[http://dx.doi.org/10.1016/j.cpcardiol.2009.10.002] [PMID: 20109979]
[http://dx.doi.org/10.1016/j.cpcardiol.2009.10.002] [PMID: 20109979]
[52]
Rungoe C, Nyboe Andersen N, Jess T. Inflammatory bowel disease and risk of coronary heart disease. Trends Cardiovasc Med 2015; 25(8): 699-704.
[http://dx.doi.org/10.1016/j.tcm.2015.03.010] [PMID: 25912602]
[http://dx.doi.org/10.1016/j.tcm.2015.03.010] [PMID: 25912602]
[53]
Wu H, Hu T, Hao H, Hill MA, Xu C, Liu Z. Inflammatory bowel disease and cardiovascular diseases: A concise review. Eur Heart J Open 2022; 2(1)
[http://dx.doi.org/10.1093/ehjopen/oeab029]
[http://dx.doi.org/10.1093/ehjopen/oeab029]
[54]
Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: A nationwide Danish cohort study. Gut 2013; 62(5): 689-94.
[http://dx.doi.org/10.1136/gutjnl-2012-303285] [PMID: 22961677]
[http://dx.doi.org/10.1136/gutjnl-2012-303285] [PMID: 22961677]
[55]
Jaiswal V, Batra N, Dagar M, et al. Inflammatory bowel disease and associated cardiovascular disease outcomes: A systematic review. Medicine 2023; 102(6): e32775.
[http://dx.doi.org/10.1097/MD.0000000000032775] [PMID: 36820570]
[http://dx.doi.org/10.1097/MD.0000000000032775] [PMID: 36820570]
[56]
Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386(4): 316-26.
[http://dx.doi.org/10.1056/NEJMoa2109927] [PMID: 35081280]
[http://dx.doi.org/10.1056/NEJMoa2109927] [PMID: 35081280]
[57]
Anisdahl K, Svatun Lirhus S, Medhus AW, Moum B, Melberg HO, Høivik ML. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study. Scand J Gastroenterol 2021; 56(10): 1163-8.
[http://dx.doi.org/10.1080/00365521.2021.1955147] [PMID: 34320885]
[http://dx.doi.org/10.1080/00365521.2021.1955147] [PMID: 34320885]
[58]
Zanoli L, Ozturk K, Cappello M, et al. Inflammation and aortic pulse wave velocity: A multicenter longitudinal study in patients with Inflammatory bowel disease. J Am Heart Assoc 2019; 8(3): e010942.
[http://dx.doi.org/10.1161/JAHA.118.010942] [PMID: 30712441]
[http://dx.doi.org/10.1161/JAHA.118.010942] [PMID: 30712441]
[59]
Patel RS, Rohit Reddy S, Llukmani A, et al. Cardiovascular manifestations in inflammatory bowel disease: A systematic review of the pathogenesis and management of pericarditis. Cureus 2021; 13(3): e14010.
[http://dx.doi.org/10.7759/cureus.14010] [PMID: 33884251]
[http://dx.doi.org/10.7759/cureus.14010] [PMID: 33884251]
